Cross-Sector entity
Of the tracked stories, 2 of 2 also mention Center for Biologics Evaluation and Research, the most common co-covered peer. Coverage clusters in clinical-trial, which accounts for 1 of those 2, with the remainder spread across 1 other category. OST-HER2 appears in 2 tracked Cross-Sector stories from August 14, 2026.
2 verified stories tracked
Last mentioned: Aug 14, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention Center for Biologics Evaluation and Research, the most common co-covered peer. Coverage clusters in clinical-trial, which accounts for 1 of those 2, with the remainder spread across 1 other category. OST-HER2 appears in 2 tracked Cross-Sector stories from August 14, 2026. The tracked stories average 2 original sources each.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering OST-HER2. Shared-story counts are live from our verified record — not editorial picks.
Interim 3-year overall survival data expected
Company expects to announce interim 3-year overall survival data from the Phase 2b OST-HER2 trial in early September 2026.
FDA Type C Statistical Methods Meeting
Meeting expected in mid-September 2026 with CBER to review statistical methods, comparator appropriateness, RMAT designation, and rolling review.
MHRA Scientific Advice Meeting
UK MHRA meeting expected in September 2026 to review statistical methods supporting the CMAA, including finalization with 2.5-year overall survival.
Company announces FDA Type C meeting and MHRA parallel review
OS Therapies announces FDA granted Type C Statistical Methods Meeting to review 2.5-year OS data for OST-HER2; MHRA Scientific Advice Meeting granted in parallel.
For healthcare regulators and health systems, OS Therapies' FDA Type C meeting on OST-HER2 will test whether historical control data can support approval in rare osteosarcoma. With MHRA running parallel advice and a biomarker qualification review pending, the case could reshape evidence standards in ultra-rare cancers.
Biotech stakeholders are watching OST-HER2's FDA Type C meeting because the statistical comparator decision could de-risk or delay a rare oncology asset. With 3-year survival data due days earlier and MHRA engagement in parallel, the event sequence is a near-term catalyst.
Source: The Kingston Whig Standard · Financialcontent
